{"relation": [["", "Number of Participants Analyzed [units: participants]", "Part I: Percentage of Participants With Minimum American College of Rheumatology (ACR) 30/50/70/90/100 at the End of Part I [units: Percentage of participants]", "Non-Responders", "ACR 30 Response", "ACR 50 Response", "ACR 70 Response", "ACR 90 Response", "ACR 100 Response"], ["Canakinumab", "175", "", "22.9", "77.1", "73.1", "64.6", "51.4", "34.3"]], "pageTitle": "Flare Prevention Study of Canakinumab in Patients With Active Systemic Juvenile Idiopathic Arthritis (SJIA) - Study Results - ClinicalTrials.gov", "title": "", "url": "https://clinicaltrials.gov/ct2/show/results/NCT00889863?sect=Xb015&view=results", "hasHeader": true, "headerPosition": "FIRST_ROW", "tableType": "RELATION", "tableNum": 18, "s3Link": "common-crawl/crawl-data/CC-MAIN-2015-32/segments/1438042988399.65/warc/CC-MAIN-20150728002308-00106-ip-10-236-191-2.ec2.internal.warc.gz", "recordEndOffset": 880028258, "recordOffset": 880012319, "tableOrientation": "HORIZONTAL", "textBeforeTable": "Period 1: \u00a0 Part I: Open Label Participant Flow for 2 periods Participants in Part II received placebo matching canakinumab subcutaneous injection every 4 weeks. At 24 weeks in Part II participants with a >0.2 mg/kg and \u22640.5 mg/kg and no flare could restart steroid tapering. If the steroid dose was \u22640.2 mg/kg participants continued to maintain their current dose for the remainder of Part II. Placebo In Part I participants received open label 4 mg/kg canakinumab subcutaneous injection every 4 weeks for up to 32 weeks. For the first 8 weeks Part Ia (4 weeks) and Ib (4 weeks) patients maintained a stable oral steroid dose (prednisone or equivalent) followed by Ic an up to 20 week steroid tapering period and then Id a 4 week stable steroid dose period. Participants were then randomized to receive either 4 mg/kg canakinumab subcutaneous injection or Placebo comparator in Part II and remained on the stable oral steroid dose for 24 weeks. At 24 weeks in Part II participants with a >0.2 mg/kg and \u2264 0.5 mg/kg and no flare could restart steroid tapering. If the steroid dose was \u2264 0.2 mg/kg participants continued to maintain their current dose for the remainder of Part II. Canakinumab Description \u00a0", "textAfterTable": "\u00a0 77 \u00a0 \u00a0 0 \u00a0 Death \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 1 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 0 \u00a0 Adverse Event \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 4 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 0 \u00a0 Unsatisfactory therapeutic effect \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 72 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 0 \u00a0 [1] No participants received placebo in Part I. [2] Patients steroid free at study entry entered Part Id directly and did not participate in Part Ic. Period 2: \u00a0 Part II: Randomized Double Blind \u00a0 \u00a0 Canakinumab \u00a0 \u00a0 Placebo \u00a0", "hasKeyColumn": true, "keyColumnIndex": 0, "headerRowIndex": 0}